To view this email as a web page, click here.

 
Angiopoietin-2 + VEGF-A to treat DME
Learn what is unique about a first-in-kind bispecific antibody that simultaneously binds and neutralizes VEGF-A and angiopoietin-2.
Continue
 
When vitrectomy offers viable therapeutic option for DME
In an era when pharmacologic therapy has become the mainstay for diabetic macular edema, pars plana vitrectomy may be a reasonable alternative in appropriate patients.
Learn more
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.